Amarin Corp Plcuk (AMRN) Change in Receivables (2013 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Change in Receivables of -$15.1 million for Q2 2026, down 222.09% year-over-year from $12.4 million in Q2 2025, and up 19.42% quarter-over-quarter from -$18.8 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Change in Receivables (2013 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Change in Receivables for 14 consecutive years, with -$15.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Receivables fell 222.09% year-over-year to -$15.1 million; the TTM figure through Jun 2026 stood at -$26.2 million (down 474.72% YoY), while the FY2025 annual figure was $4.6 million, up 140.35% from the prior year.
- Change in Receivables climbed to -$15.1 million in Q2 2026 per AMRN's latest filing, from -$18.8 million in the prior quarter.
- Across five years, Change in Receivables topped out at $33.7 million in Q2 2022 and bottomed at -$53.4 million in Q1 2022.
- Historically, Change in Receivables has averaged -$3.9 million across 5 years, with a median of -$403500.0 in 2023.
- On a YoY basis, Change in Receivables climbed as much as 175.05% in 2024 and fell as far as 3248.18% in 2024.
- Amarin Corp Plc\Uk's Change in Receivables stood at $7.6 million in 2022, then surged by 46.67% to $11.2 million in 2023, then dropped by 13.67% to $9.6 million in 2024, then plunged by 104.95% to -$477000.0 in 2025, then sank by 3072.75% to -$15.1 million in 2026.
- Business Quant data shows AMRN's Change in Receivables at -$15.1 million in Q2 2026, -$18.8 million in Q1 2026, and -$477000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -15.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.13 Mn |
| Jun 30, 2026 | -15.13 Mn |
| Mar 31, 2026 | -18.78 Mn |
| Mar 31, 2026 | -18.78 Mn |
| Dec 31, 2025 | -477,000.00 |
| Dec 31, 2025 | -477,000.00 |
| Sep 30, 2025 | 8.18 Mn |
| Sep 30, 2025 | 8.18 Mn |
| Jun 30, 2025 | 12.40 Mn |
| Jun 30, 2025 | 12.40 Mn |
| Mar 31, 2025 | -15.55 Mn |
| Mar 31, 2025 | -15.55 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Sep 30, 2024 | -11.05 Mn |
| Jun 30, 2024 | 7.89 Mn |
| Jun 30, 2024 | 7.89 Mn |
| Mar 31, 2024 | -17.76 Mn |
| Mar 31, 2024 | -17.76 Mn |